NervGen Pharma Corp.
NGEN.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -53.85% | 35.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.18% | 11.18% | |||
| Operating Income | 4.18% | -11.18% | |||
| Income Before Tax | 54.14% | -139.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.14% | -139.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.14% | -139.19% | |||
| EBIT | 4.18% | -11.18% | |||
| EBITDA | 4.19% | -11.20% | |||
| EPS Basic | 54.92% | -134.96% | |||
| Normalized Basic EPS | 54.90% | -135.39% | |||
| EPS Diluted | 54.92% | -134.96% | |||
| Normalized Diluted EPS | 54.90% | -135.39% | |||
| Average Basic Shares Outstanding | 1.68% | 1.82% | |||
| Average Diluted Shares Outstanding | 1.68% | 1.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||